Continuous levodopa infusion is better-for now

Movement Disorders

Volumn 30, Issue 4, 2015, Pages 443-445

  Nutt, John G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; APOMORPHINE; CARBIDOPA; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; LEVODOPA; ANTIPARKINSON AGENT; GEL;

AKINESIA; BRAIN DEPTH STIMULATION; CONTINUOUS INFUSION; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG HALF LIFE; DYSKINESIA; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROJEJUNOSTOMY; HUMAN; IMPULSE CONTROL DISORDER; MORBIDITY; MOTOR DYSFUNCTION; NERVE ENDING; NEUROPHARMACOLOGY; NONHUMAN; OPEN STUDY; PARKINSON DISEASE; PATIENT CARE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; FEMALE; GEL; INTESTINE; MALE; PHYSIOLOGY;

ANTIPARKINSON AGENTS; APOMORPHINE; CARBIDOPA; FEMALE; GELS; HUMANS; INTESTINES; LEVODOPA; MALE; PARKINSON DISEASE;

EID: 84926170312     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26169     Document Type: Editorial

References (21)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
2. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
3. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
4. Tanaka H, Kannari K, Maeda T, et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999;10:631-634.
5. Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127:2747-2754.
6. Schultz W. Reward signaling by dopamine neurons. Neuroscientist 2001;7:293-302.
7. Goerendt IK, Messa C, Lawrence AD, et al. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 2003;126:312-325.
8. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-149.
9. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930-1933.
10. Nutt JG, Carter JH, Lea ES, et al. Motor fluctuations during continous levodopa infusions in patients with Parkinson's disease. Mov Disord 1997;12:285-292.
11. Gancher ST, Nutt JG, Woodward WR. Time-course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 1992;52:504-510.
12. Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001;124:331-340.
13. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-211.
14. Brittain JS, Sharott A, Brown P. The highs and lows of beta activity in cortico-basal ganglia loops. Eur J Neurosci 2014;39:1951-1959.
15. Grahn PJ, Mallory GW, Khurram OU, et al. A neurochemical closed-loop controller for deep brain stimulation: toward individualized smart neuromodulation therapies. Front Neurosci 2014;8:169.
16. Nyholm D. Duodopa(R) treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012;18:916-929.
17. Nyholm D, Johansson A, Aquilonius SM, et al. Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease. Clin Neuropharmacol 2012;35:6-14.
18. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27.
19. Lotti VJ, Porter CC. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors. J Pharmacol Exp Ther 1970;172:406-415.
20. Jonkers N, Sarre S, Ebinger G, et al. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm 2001;108:559-570.
21. Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov Disord 2012;27:750-753.